XML 42 R25.htm IDEA: XBRL DOCUMENT v3.19.3
Financial Instruments and Derivative Instruments (Tables)
9 Months Ended
Sep. 29, 2019
Financial Instruments and Derivative Instruments  
Schedule of carrying amount and estimated fair market value of the company's long-term debt, including current portion

September 29,

December 31,

    

2019

    

2018

(in millions)

Carrying amount

$

344.5

$

355.0

Estimated fair value

$

345.3

$

355.4

Schedule of fair value of financial assets and liabilities

Fair Value Measurement at September 29, 2019 Using:

Quoted Prices in Active

Significant Other

Significant

Markets for Identical

Observable

Unobservable

Assets

Inputs

Inputs

    

Total

    

(Level 1)

    

(Level 2)

    

(Level 3)

(in millions)

Assets

Plan asset for deferred compensation(1)

$

2.4

$

2.4

$

$

Interest rate swaps (1)

$

1.5

$

$

1.5

$

Total assets

$

3.9

$

2.4

$

1.5

$

Liabilities

Plan liability for deferred compensation(2)

$

2.4

$

2.4

$

$

Designated foreign currency hedges (4)

$

0.3

$

$

0.3

$

Total liabilities

$

2.7

$

2.4

$

0.3

$

Fair Value Measurements at December 31, 2018 Using:

Quoted Prices in Active

Significant Other

Significant

Markets for Identical

Observable

Unobservable

    

Assets

Inputs

 Inputs

Total

    

(Level 1)

    

(Level 2)

    

(Level 3)

(in millions)

Assets

Plan asset for deferred compensation(1)

$

2.6

$

2.6

$

$

Interest rate swaps (1)

$

6.5

$

$

6.5

$

Total assets

$

9.1

$

2.6

$

6.5

$

Liabilities

Plan liability for deferred compensation(2)

$

2.6

$

2.6

$

$

Redeemable financial instrument(3)

$

2.8

$

$

$

2.8

Total liabilities

$

5.4

$

2.6

$

$

2.8

(1)

Included on the Company’s consolidated balance sheet in other assets (other, net).

(2)

Included on the Company’s consolidated balance sheet in accrued compensation and benefits.

(3)

Included on the Company’s consolidated balance sheet in accrued expenses and other liabilities and relates to a mandatorily redeemable equity instrument as part of the Apex Valves Limited (“Apex”) acquisition in 2015.

(4)

Included on the Company’s consolidated balance sheet in accrued expenses and other liabilities.